entertainment -WSS

entertainment

author：explore 2025-10-03 00:07:03 - browse：45

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Why don't Americans have at

Wikipedia

WSS

Patient advocates debate FDA's accelerated approval process

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Abortion pill Supreme Court ruling could impact entire drug industry

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Long Covid research funding gets a major boost from NIH

Long Covid research funding gets a major boost from NIH

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

ChatGPT in medicine: STAT answers readers' burning questions

Report cites 'urgent' need to recruit more diverse clinical trial participants

Apple is now the first public company to be valued at $3 trillion

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Hepatitis C has a cure — but many Americans still lack access to it

Resistance to opioid

How one medical school became remarkably diverse

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

entertainment

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Resistance to opioid

Juul documents reveal insider tactics on political lobbying

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Covid vaccine financial winners and losers, from Pfizer to Novavax

Wikipedia

Wikipedia

focus

entertainment